M&A

News

Vanda bats away unwanted Cycle, Future Pak takeover bids

Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.

News

Cycle Pharma makes $466m takeover bid for Vanda

UK group Cycle Pharma has made an unsolicited takeover bid to buy Vanda Pharma of the US, which is already fending off an overture from Future Pak.

News

Digital therapeutics firm Akili agrees $34 million takeover

In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeuti

News

Update: MSD confirms $3bn takeover of EyeBio

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular

News

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill

News

Asahi Kasei makes $1.1bn bid to buy Calliditas

Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to expand internationally in healthcare.

Vanda bats away unwanted Cycle, Future Pak takeover bids

Cycle Pharma makes $466m takeover bid for Vanda

Digital therapeutics firm Akili agrees $34 million takeover

Update: MSD confirms $3bn takeover of EyeBio

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

Asahi Kasei makes $1.1bn bid to buy Calliditas

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

M&A

Editor's Picks